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Abstract
Background: The World Health Organization (WHO), like many other organisations around the world, has recognised the
need to use more rigorous processes to ensure that health care recommendations are informed by the best available research
evidence. This is the ninth of a series of 16 reviews that have been prepared as background for advice from the WHO Advisory
Committee on Health Research to WHO on how to achieve this.
Objectives: We reviewed the literature on grading evidence and recommendations in guidelines.
Methods: We searched PubMed and three databases of methodological studies for existing systematic reviews and relevant
methodological research. We did not conduct a full systematic review ourselves. Our conclusions are based on the available
evidence, consideration of what WHO and other organisations are doing and logical arguments.
Key questions and answers: Should WHO grade the quality of evidence and the strength of recommendations?
• Users of recommendations need to know how much confidence they can place in the underlying evidence and the
recommendations. The degree of confidence depends on a number of factors and requires complex judgments. These judgments
should be made explicitly in WHO recommendations. A systematic and explicit approach to making judgments about the quality
of evidence and the strength of recommendations can help to prevent errors, facilitate critical appraisal of these judgments, and
can help to improve communication of this information.
What criteria should be used to grade evidence and recommendations?
• Both the quality of evidence and the strength of recommendations should be graded. The criteria used to grade the strength
of recommendations should include the quality of the underlying evidence, but should not be limited to that.
• The approach to grading should be one that has wide international support and is suitable for a wide range of different types
of recommendations. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, which
is currently suggested in the Guidelines for WHO Guidelines, is being used by an increasing number of other organizations
internationally. It should be used more consistently by WHO. Further developments of this approach should ensure its wide
applicability.
Should WHO use the same grading system for all of its recommendations?
• Although there are arguments for and against using the same grading system across a wide range of different types of 
recommendations, WHO should use a uniform grading system to prevent confusion for developers and users of 
recommendations.
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Background
The World Health Organization (WHO), like many other
organisations around the world, has recognised the need
to use more rigorous processes to ensure that health care
recommendations are informed by the best available
research evidence. This is the ninth of a series of 16
reviews that have been prepared as background for advice
from the WHO Advisory Committee on Health Research
to WHO on how to achieve this.
For over 25 years a growing number of organisations have
employed various systems to grade the quality of evidence
(sometimes called levels of evidence) and the strength of
recommendations [1]. Unfortunately, different organisa-
tions use various grading systems, which may lead to con-
fusion among consumers.
Groups making recommendations always make judge-
ments about the quality of evidence and the balance of
benefits and downsides (harms, burden and costs). Fre-
quently these judgements are made implicitly rather than
explicitly and judgements about the quality of evidence
are confused with judgements about the balance of bene-
fits and downsides. Many systems that are used to grade
the quality of evidence and the strength of recommenda-
tions also confuse these judgements by equating the
strength of recommendation with the quality of evidence,
for example by grading recommendations for which there
is high quality evidence as strong, without explicitly con-
sidering the balance of benefits and downsides.
Knowing the quality of evidence is essential, but not suffi-
cient for making judgements about the strength of a rec-
ommendation. For instance, high quality evidence from
well executed randomized controlled trials showed that
oral anticoagulation administered for more than one year
reduces the risk for recurrent thromboembolic events in
patients after a first episode of spontaneous deep venous
thrombosis. However, because oral anticoagulation is
associated with harms (bleeding risk), burden (taking
medication and monitoring anticoagulation levels) and
cost (anticoagulation clinics or monitoring devices) the
recommendation to anticoagulate all patients is weak
because the benefits and downsides are finely balanced
and individual patients will make different choices [2].
Both judgements about the quality of evidence and about
the strength of a recommendation are complex and
require consideration of a number of factors.
In this paper we addressed the following questions:
￿ Should WHO grade the quality of evidence and the
strength of recommendations?
￿ What criteria should be used to grade evidence and rec-
ommendations?
￿ Should WHO use the same grading system for all of its
recommendations?
Questions related to what evidence should be included,
how it should be synthesized and reported are addressed
in other papers in this series [3-5].
What WHO is doing now?
WHO groups (e.g. WHO Europe) have acknowledged the
need for evaluating or developing a grading system [6,7],
and the Guidelines for WHO Guidelines recommend
using a specific, uniform grading system [8]. However,
this system, the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach,
has scarcely been used within WHO [9,10]. Some WHO
groups have developed their own grading systems [11,12],
despite of the guidelines for WHO guidelines suggestion
to use GRADE. Most have not explicitly graded either the
quality of evidence or the strength of recommendations
[13,14].
What other organisations are doing
Most, but not all organizations that develop guidelines
use a grading system to express the strength of a recom-
mendation or the quality of evidence. For example, the US
Preventive Services Task Force (USPSTF) uses a grading
system that assigns one of three grades of evidence: good,
fair, or poor [15]. The Task Force uses its assessment of the
evidence and magnitude of net benefit to make a recom-
mendation, coded as a letter: from A (strongly recom-
mended) to D (recommend against). The UK National
Institute for Health and Clinical Excellence (NICE) has
not yet made a decision as to which grading system to use
[16]. The Scottish Intercollegiate Guideline Network
(SIGN) has developed its own grading system for applica-
tion to SIGN guidelines [17]. The Australian Medical
Research Council is currently developing a grading system
that will probably include grading recommendations
according to strength of recommendations and quality of
evidence [18]. The US Task Force on Community Preven-
tive Services uses a system in which the quality of the evi-
dence of effectiveness links directly the strength of the
recommendation [19,20]. Professional organizations use
a variety of systems, many of them, however, based on
two prominent grading approaches: the system derived
from the Canadian Task Force on the Periodic Health
Examination [1,21] and a successor of that system, the
Oxford Centre for Evidence Based Medicine approach
[22].
More recently, medical societies have begun to form col-
laborations within specialties to develop grading systemsHealth Research Policy and Systems 2006, 4:21 http://www.health-policy-systems.com/content/4/1/21
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on their own. For example a group of specialty societies in
rehabilitation sciences formed a panel to develop an
approach to grading the quality of evidence and strength
of recommendations [23]. This panel developed a set of
criteria for grading the strength of both the evidence and
the recommendation. Similarly, the world leading urol-
ogy associations have come together to adopt a uniform
grading system and approach that would be useful for
urologists around the world rather than each association
using a different grading system [24]. This latter collabo-
ration named, Evidence Based Urology, is exploring using
the GRADE approach. The GRADE approach is being used
increasingly by organisations around the world [25-28],
although in some cases with slight modifications [29]. It
has been used for public health questions such as the
pharmacological management of human influenza
A(H5N1) infection (avian flu) [30], although it more
commonly has been used for clinical questions up to now.
A group of family practice and primary care journals has
also developed a system to grade the strength of a recom-
mendation [31].
Methods
The methods used to prepare this review are described in
the introduction to this series [32]. Briefly, the key ques-
tions addressed in this paper were vetted amongst the
authors and the ACHR Subcommittee on the Use of
Research Evidence (SURE). We did not conduct a full sys-
tematic review. We reviewed existing guidelines for guide-
lines to identify grading system currently in use. We also
searched PubMed using (grading system) and (methods)
(MESH headings/keywords) for systematic reviews and
studies of methods for grading the quality of evidence. In
addition, we searched databases maintained by the
Agency for Healthcare Research and Quality (AHRQ,
[33]) and the Guidelines International Network (GIN,
[34]). These searches were supplemented with informa-
tion obtained directly from guideline development organ-
izations and our own files. Because of our involvement
with organizations that produce guidelines and prior
work with grading systems, in particular the GRADE sys-
tem, we had in depth knowledge about several systems
[25,28,29,35,36].
Findings
We identified one systematic review dealing with the eval-
uation of grading systems. In 2002, the US Agency for
Healthcare Research and Quality (AHRQ) published a
systematic review of existing systems to grade the quality
of evidence and strength of recommendations [37]. The
AHRQ review considered 40 systems until the year 2000
that addressed grading the strength of a body of evidence.
The important domains and elements for the systems to
grade the strength of evidence that the authors agreed on
were quality (the aggregate of quality ratings for individ-
ual studies, predicated on the extent to which bias was
minimized), quantity (magnitude of effect, numbers of
studies, and sample size or power) and consistency (for
any given topic, the extent to which similar findings are
reported using similar and different study designs).
More recently, independent work by the Canadian Opti-
mal Medication Prescribing and Utilization Service
(COMPUS) used a detailed process to evaluate and select
an evidence grading system and expanded the work by
AHRQ (while accepting it) until the year 2005 [38]. COM-
PUS, which identifies, evaluates, promotes and facilitates
best practices in drug prescribing and use among health
care providers and consumers in Canada [39], is a nation-
ally coordinated program, funded by Health Canada and
delivered by the Canadian Coordinating Office for Health
Technology Assessment (CCOHTA, [39]). They assem-
bled a working group of internal researchers, information
specialists, methodology experts, and external researchers
to update the work of AHRQ. COMPUS searched for and
selected review articles for the period 2000 to 2005. This
resulted in more than 3,000 citations for selection. Eleven
review articles were selected for further analysis based on
a priori selection criteria specified by the working group.
Nearly 50 evidence grading systems were identified from
the 11 review articles. Canadian and international experts
in evidence evaluation methodology helped identify an
additional 10 instruments or systems not included in the
list of identified grading systems. The identified instru-
ments and systems were evaluated using the AHRQ evalu-
ation grids. The highest scoring instruments were the
GRADE and the SIGN approach [38]. A second round of
expert consultation and stakeholder input from all inter-
ested parties confirmed the selection of these instruments.
The GRADE system was developed through an intensive
international collaboration of methodologists, guideline
developers and clinicians and incorporates the factors
identified in the AHRQ review and described above
[35,36].
Should WHO grade the quality of evidence and the 
strength of recommendations?
We did not identify published studies that compared
graded with non-graded recommendations. The only evi-
dence we are aware of are three unpublished studies. The
first was conducted by UpToDate®, an electronic textbook,
that asked a small group of users to compare graded with
non-graded recommendations and explore – in a focus
group setting – reasons for their answers (UpToDate®, per-
sonal communication). The second is our own study ask-
ing a small group of the general public interested in health
care issues (Akl E, et al, manuscript in preparation). The
third is a study by researchers in Norway who provided
patients with back problems with graded evidence of theHealth Research Policy and Systems 2006, 4:21 http://www.health-policy-systems.com/content/4/1/21
Page 4 of 7
(page number not for citation purposes)
effects of alternative interventions graded with the
GRADE approach. Users of the website intuitively under-
stood the meaning of the quality grades for each outcome
(Claire Glenton, personal communication). The findings
of these evaluations suggested that users preferred graded
over non-graded recommendations.
Despite the lack of stronger direct evidence, there is agree-
ment among most guideline developers that grading the
quality of evidence has advantages, because health care
decisions involve a trade-off between likely benefits on
the one hand, and downsides (harms, burden and costs)
on the other hand [40]. To integrate these recommenda-
tions with their own judgment, guideline users need to
understand the basis for the recommendations that guide-
lines offer them. A systematic approach to grading the
strength of recommendations should minimize bias and
aid interpretation about benefits and downsides. In addi-
tion, a systematic and explicit approach to making judge-
ments about the quality of evidence and the strength of
recommendations is likely to help prevent errors, facilitate
critical appraisal of these judgements, and can help
improve communication of this information [36].
What criteria should be used to grade evidence and 
recommendations?
In a series of 16 international meetings and correspond-
ence over five years the GRADE Working Group has
derived a set of criteria to assess the quality of evidence
(Table 1) and the strength of recommendations (Table 2)
[25,29,35,36,41,42]. The GRADE system has several
advantages over other systems including explicit defini-
tions and sequential judgments during the grading proc-
ess; a detailed description of the criteria for the quality of
evidence for single outcomes and for the overall quality of
the evidence; weighing the relative importance of out-
comes; consideration of the balance between health ben-
efits versus harms, burdens and cost; and the
development of evidence profiles and summaries of find-
ings. In addition the GRADE group is supported by an
international collaboration [36]. The main limitation and
criticism of the GRADE system is its complexity. Work in
progress is addressing this limitation including the devel-
opment of user friendly software to develop evidence pro-
files (G. Vist, personal communication and [26,29]).
Should WHO use the same grading system for all of its 
recommendations?
We did not identify evidence for or against using a single
grading system for all types of recommendations, includ-
ing clinical, public health and health policy recommenda-
tions. The arguments for and against using a single
grading system are summarised in Table 3. The most
important reasons for using a consistent system are a)
minimising confusion amongst users of WHO recom-
mendations; b) the risk of bias if groups can select a sys-
tem that makes the quality of evidence and the strength of
recommendations look better for their preferred interven-
tions; and c) being intellectually honest about recognising
the limits of the evidence rather than having a double
standard. If an approach can be identified that is suitable
across a wide range of interventions and contexts both
methodologically and politically, the advantages out-
weigh the disadvantages.
Some developers and users of GRADE believe that GRADE
can be consistently and usefully applied across clinical
and non-clinical interventions, based on conceptual argu-
ments and experience up to now applying this approach
to a wide range of interventions, including public health
and health system interventions. Others disagree because
they believe it is unlikely to be an appropriate approach
for some areas for the reasons summarised in table 3.
There is not yet an empirical evidence base with which to
mediate this disagreement for GRADE or any other grad-
ing system. Up to now GRADE has been used mostly for
clinical interventions and few examples of its use with
public health questions have been published. There is an
Table 1: GRADE quality assessment criteria
Quality of evidence Study design Lower if * Higher if *
High Randomised trial Study quality:
-1 Serious limitations






-1 High probability of Reporting bias
Strong association:
+1 Strong, no plausible confounders, consistent and direct evidence**
+2 Very strong, no major threats to validity and direct evidence***
+1 Evidence of a Dose response gradient




* 1 = move up or down one grade (for example from high to intermediate) 2 = move up or down two grades (for example from high to low)
** A statistically significant relative risk of >2 (< 0.5), based on consistent evidence from two or more observational studies, with no plausible 
confounders
*** A statistically significant relative risk of > 5 (< 0.2) based on direct evidence with no major threats to validityHealth Research Policy and Systems 2006, 4:21 http://www.health-policy-systems.com/content/4/1/21
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ongoing international collaborative effort to apply the
GRADE approach to public health and health systems
interventions, and it is possible that modifications may be
needed to ensure its usefulness for non-clinical interven-
tions. For example, in one recent review of drug policies
the authors felt that it was important to distinguish
between different types of observational studies (inter-
rupted time-series analyses and controlled before-after
studies) when making judgements about the quality of
evidence for important outcomes [43].
Discussion
WHO has made a decision to use a grading system to
grade the quality of evidence and strength of recommen-
dations that is sensible and is being used widely, the
GRADE system [36]. WHO has been involved in the
development of this system from the beginning, and con-
sideration has been given to the potential for application
of the system to WHO guidelines in developing the
GRADE approach. This might have been expected to facil-
itate the dissemination and adoption of this approach by
WHO guideline developers. However, interest in GRADE
workshops at WHO has been limited, there is not a tradi-
tion of grading the quality of evidence or strength of rec-
ommendations at WHO, and few resources have been
invested in supporting the use of GRADE specifically, or in
supporting more rigorous guidelines development meth-
ods generally.
More recently, however, the WHO rapid advice guideline
panel for the pharmacological management of human
infection with avian influenza A (H5N1) virus applied
GRADE successfully [30] and several WHO guidelines are
under development using GRADE (Sue Hill, personal
communication). In general, the evidence that graded rec-
ommendations have advantages over non-graded recom-
mendations is limited, but there are strong arguments,
including the clear and transparent communication of
how much confidence users can place in recommenda-
tions and the evidence underlying them. Another limita-
tion is that both the quality of evidence and the strength
of recommendations exist on a continuum. Categoriza-
tion of quality into four categories and recommendations
for or against treatments into two grades, strong and weak,
may oversimplify complex health care recommendations,
but guidelines consumers are generally likely to benefit
from this simplification as they are most interested in
which recommendations to follow.
Further work
We have found a large body of work on the development
and evaluation of various grading systems. Problems have
arisen because many different grading systems exist.
Future efforts should focus on forging a consensus on
using a sensible and uniform approach to grade the qual-
ity of evidence and strength of recommendations, build-
ing on the work of the GRADE working group. Use of the
Table 3: Pros and cons of using the same system for grading evidence and formulating recommendations for a wide range of health 
care interventions, including clinical and non-clinical interventions
Arguments for having a common approach Arguments against having a common approach
• Having less demanding systems for some kinds of questions might 
result in false positive conclusions.
• People with vested interests in particular interventions could choose 
the system that makes their intervention look best.
• People with vested interests in particular evaluation approaches could 
choose the system that makes their preferred evaluation approach look 
best.
• Having different systems for different types of interventions might be 
confusing.
• It is intellectually honest to recognise the limits of evidence where this 
is appropriate.
• Admitting the limitations of evidence, if this is appropriate, might 
promote more and better research.
• Having an infeasible system for some kinds of questions might result in 
false negative conclusions.
• False negative conclusions due to inappropriate evaluation 
requirements may have negative political and health consequences; for 
example, effective programs that cannot be studied with randomised 
trials might experience funding cuts.
• Interventions that cannot be studied with randomised trials might not 
be evaluated.
• A single system may not discriminate adequately within the range of 
evidence that is appropriate to consider for clinical and non-clinical 
interventions.
• A system that can adequately address evidence across a wide range of 
interventions and contexts may be overly complex.
Table 2: Decisions about the strength of a recommendation
Factors that can weaken the strength of a recommendation Explanation
Lower quality evidence Will create greater uncertainty about the size of the (relative) effects (benefits and harms)
Uncertainty about the balance of benefits versus harms and burdens Uncertainty about the baseline risk, prevalence of a problem or health status, which could affect the 
size of the (absolute) effects
Uncertainty or differences in values Uncertainty about the relative importance of the benefits and downsides to those affected, or 
differences in how important they are to different people, which could affect the balance between the 
benefits versus harms and burden
Marginal net benefits or downsides The anticipated net benefits or downsides are small (and uncertain)
Uncertainty about whether the net benefits are worth the costs Uncertainty related to lack of information about the cost or whether the resource expenditure is 
justified by the anticipated benefitHealth Research Policy and Systems 2006, 4:21 http://www.health-policy-systems.com/content/4/1/21
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GRADE system by WHO, as is currently recommended by
the Guidelines for WHO Guidelines, could help by
obtaining more experience, particularly with non-clinical
interventions, contribute to improvements in the existing
system, contribute to agreeing on a common interna-
tional approach to grading of recommendations and help
to ensure the quality and transparency of the judgements
that are made across various groups that make recommen-
dations on behalf of WHO. Development of software and
a detailed manual to simplify the use of the GRADE sys-
tem is underway and should facilitate the use of this sys-
tem and its further development.
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